CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 13 enrolled
Drug / intervention
durvalumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03122496
NCT03122496Phase 1Completed
CompareCT.gov

A Pilot Study of Durvalumab (MEDI4736) With Tremelimumab in Combination With Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer

Memorial Sloan Kettering Cancer Center·interventional·Posted Apr 20, 2017·Updated Jun 8, 2022

In Brief

A Phase 1 clinical trial evaluating durvalumab, tremelimumab, and 1 other intervention for Metastatic Anaplastic Thyroid Cancer. Completed, enrolled 13 participants across 8 sites.

Detailed Summary

The purpose of this study is to test the safety of durvalumab (MEDI4736) and tremelimumab in combination with radiation therapy and find out what effects, if any, this combination has on people, and whether it improves overall survival.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Anaplastic Thyroid Cancer
CountriesUnited States
CollaboratorsAstraZeneca

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedApr 20, 2017
Enrollment StartApr 25, 2017
Primary CompletionJun 3, 2022
TodayJul 1, 2026
Enrollment to primary: 5.1 yearsPosted 9.2 years ago

Interventions

durvalumabdrug

Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.

tremelimumabdrug

Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.

Stereotactic Body Radiotherapy (SBRT)radiation

SBRT at 9Gy x 3 per standard of care given within 2 weeks after the completion of Cycle 1 of durvalumab (MEDI4736) and tremelimumab